Palvella Therapeutics, Inc. (PVLA)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$125.10-1.02%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Palvella Therapeutics, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	16,667
EPS	—	-2.138
Annual ending 2026-12-31
Revenue	—	26,667
EPS	—	-6.598
Annual ending 2027-12-31
Revenue	—	23.58M
EPS	—	-8.338

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Achieve first FDA approval by first half of 2027	The company targets FDA approval by early 2027.	Improving	FDA approval not granted by 2027-06-30	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Manage cash flow and losses to sustain financial health	Management is focused on financial stability despite current losses.	Under Pressure	Operating loss or cash flow worse than -$14.9M or -$10.9M respectively in 2026-Q1	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
NDA submission on track for second half of 2026	Palvella aims to submit its NDA in the second half of 2026.	Improving	NDA submission delayed beyond 2026-12-31	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-8.34

$-6.54 → $-8.34 · observed estimates

FY2027 revenue$0.02B

$0.03B → $0.02B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-6.54	$28,699,963	9 / 10
2026-07-25	$-6.54	$28,699,963	9 / 10
2026-07-26	$-6.54	$28,699,963	9 / 10
2026-07-27	$-6.54	$28,699,963	9 / 10
2026-07-28	$-6.54	$28,699,963	9 / 10
2026-07-29	$-6.54	$28,699,963	9 / 10
2026-07-30	$-6.38	$30,550,150	10 / 13
2026-07-31	$-6.54	$28,699,963	9 / 10
2026-08-01	$-6.54	$28,699,963	9 / 10
2026-08-02	$-6.38	$30,550,150	10 / 13
2026-08-03	$-6.54	$28,699,963	9 / 10
2026-08-04	$-6.54	$28,699,963	9 / 10
2026-08-05	$-6.99	$29,027,000	10 / 13
2026-08-06	$-6.54	$28,699,963	9 / 10
2026-08-07	$-7.81	$27,363,837	9 / 10
2026-08-08	$-7.40	$29,025,380	10 / 13
2026-08-09	$-7.40	$29,025,380	10 / 13
2026-08-10	$-7.40	$29,025,380	10 / 13
2026-08-12	$-7.81	$27,363,837	9 / 10
2026-08-13	$-7.81	$27,363,837	9 / 10
2026-08-14	$-7.81	$27,363,837	9 / 10
2026-08-15	$-7.81	$27,363,837	9 / 10
2026-08-16	$-7.81	$27,363,837	9 / 10
2026-08-17	$-7.81	$27,363,837	9 / 10
2026-08-18	$-7.81	$27,363,837	9 / 10
2026-08-19	$-7.81	$27,363,837	9 / 10
2026-08-20	$-7.81	$27,363,837	9 / 10
2026-08-21	$-7.81	$27,363,837	9 / 10
2026-08-22	$-7.81	$27,363,837	9 / 10
2026-08-23	$-7.81	$27,363,837	9 / 10
2026-08-24	$-7.81	$27,363,837	9 / 10
2026-08-25	$-7.81	$27,363,837	9 / 10
2026-08-26	$-7.81	$27,363,837	9 / 10
2026-08-27	$-7.81	$27,363,837	9 / 10
2026-08-28	$-7.81	$27,363,837	9 / 10
2026-08-29	$-8.10	$28,034,760	9 / 10
2026-08-30	$-8.10	$28,034,760	9 / 10
2026-08-31	$-8.10	$28,034,760	9 / 10
2026-09-01	$-8.10	$28,034,760	9 / 10
2026-09-02	$-8.10	$28,034,760	9 / 10
2026-09-03	$-8.10	$28,034,760	9 / 10
2026-09-04	$-8.10	$28,034,760	9 / 10
2026-09-05	$-8.31	$27,922,171	9 / 10
2026-09-06	$-8.31	$27,922,171	9 / 10
2026-09-07	$-8.31	$27,922,171	9 / 10
2026-09-08	$-8.31	$27,922,171	9 / 10
2026-09-09	$-8.31	$27,922,171	9 / 10
2026-09-10	$-8.31	$27,922,171	9 / 10
2026-09-11	$-8.31	$27,922,171	9 / 10
2026-09-12	$-8.31	$27,893,600	9 / 10
2026-09-13	$-8.31	$27,893,600	9 / 10
2026-09-14	$-8.31	$27,893,600	9 / 10
2026-09-15	$-8.31	$27,893,600	9 / 10
2026-09-16	$-8.31	$27,893,600	9 / 10
2026-09-17	$-8.31	$27,893,600	9 / 10
2026-09-18	$-8.31	$27,893,600	9 / 10
2026-09-19	$-8.31	$27,893,600	9 / 10
2026-09-20	$-8.31	$27,893,600	9 / 10
2026-09-21	$-8.31	$27,893,600	9 / 10
2026-09-22	$-7.98	$27,187,360	9 / 10
2026-09-23	$-7.98	$27,187,360	9 / 10
2026-09-24	$-7.98	$27,187,360	9 / 10
2026-09-25	$-7.98	$27,187,360	9 / 10
2026-09-26	$-7.98	$27,187,360	9 / 10
2026-09-27	$-7.98	$27,187,360	9 / 10
2026-09-28	$-7.98	$27,187,360	9 / 10
2026-09-29	$-7.98	$27,187,360	9 / 10
2026-09-30	$-7.98	$27,187,360	9 / 10
2026-10-01	$-7.98	$27,187,360	9 / 10
2026-10-02	$-7.98	$27,187,360	9 / 10
2026-10-03	$-7.98	$27,187,360	9 / 10
2026-10-04	$-7.98	$27,187,360	9 / 10
2026-10-05	$-7.98	$27,187,360	9 / 10
2026-10-06	$-7.98	$27,187,360	9 / 10
2026-10-07	$-7.98	$27,187,360	9 / 10
2026-10-08	$-7.98	$27,187,360	9 / 10
2026-10-09	$-7.98	$27,187,360	9 / 10
2026-10-10	$-7.98	$27,187,360	9 / 10
2026-10-11	$-7.98	$27,187,360	9 / 10
2026-10-12	$-7.98	$27,187,360	9 / 10
2026-10-13	$-8.39	$25,469,560	9 / 10
2026-10-14	$-8.39	$25,469,560	9 / 10
2026-10-15	$-8.39	$25,469,560	9 / 10
2026-10-16	$-8.39	$25,469,560	9 / 10
2026-10-17	$-8.39	$25,469,560	9 / 10
2026-10-18	$-8.28	$24,474,106	10 / 11
2026-10-19	$-8.28	$24,474,106	10 / 11
2026-10-20	$-8.28	$24,474,106	10 / 11
2026-10-21	$-8.28	$24,470,919	10 / 11
2026-10-22	$-8.34	$23,583,419	10 / 11
2026-10-23	$-8.34	$23,582,425	10 / 11
2026-10-24	$-8.34	$23,582,425	10 / 11

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	16	0	0
2026-06-01	16	0	0
2026-07-01	15	0	0
2026-08-01	15	0	0
2026-09-01	15	0	0
2026-10-01	16	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 16 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades1 maintains

Recent actions · Sep 25–Oct 24 · 1 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

Raymond JamesOct 16

$226.00New observation · no comparable prior

H.C. WainwrightOct 12 · prior Jul 22

$270.00 → $246.00-8.9%

$0$148.50$297.00

0 raises · 1 cuts · 0 unchanged · 1 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Achieve first FDA approval by first half of 2027Direct metric needs a verified mapping
Manage cash flow and losses to sustain financial healthPublished status: Under Pressure
NDA submission on track for second half of 2026Direct metric needs a verified mapping

Next proof point

Nov 10, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.9%Typical daily move · historical

Downside history

-31.1%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Palvella Therapeutics, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a speculative, development-stage healthcare business, with a long-term thesis tied to regulatory progress and possible product commercialization. The thesis is in a watch state: management has kept the main regulatory milestone on track, but recent performance is weak and earnings quality is fragile.

What's priced into Palvella Therapeutics, Inc.

PVLA is described as cheap versus peers, though confidence in that valuation assessment is low. The evidence says weak execution is reflected, but not a broader combination of expensive valuation and turbulence; the expectations gap is negative, suggesting current expectations may still be demanding.

What the fundamentals likely do

Near term, consecutive earnings misses and an elevated risk of another miss leave results vulnerable, and the recent signal has shifted from mildly favorable to mixed. Over the multi-year view, management is on track with a QTORIN rapamycin NDA submission in the second half of 2026, while launch preparation and pipeline development remain areas to watch.

What Palvella Therapeutics, Inc. hinges on

The key swing factor is whether PVLA completes the planned NDA submission and can prepare for a potential U.S. launch in the first half of 2027, contingent on approval. Near term, another guidance cut or further weakening in jobs data would add pressure, while strong results and guidance from healthcare bellwethers could support sector momentum.